FDA sets path for key new diabetes device

CHICAGO,  (Reuters) – The U.S. Food and Drug  Administration issued new guidelines to medical device makers  developing a potentially revolutionary device for type 1  diabetes, saying they should speed its delivery to patients.

The guidelines reflect months of behind-the-scenes  negotiations with patient advocates, medical device makers and  researchers working to develop an artificial pancreas — a  complex system of pumps and sensors aimed at automating the  care and treatment of type 1 diabetes.

Diabetes advocates had feared the FDA would set the bar too  high, making regulations so cumbersome that it would delay  access to diabetics in the United States.

“This guidance was developed in a way to account for  innovation,” Charles “Chip” Zimliki, who heads an FDA  initiative to speed up availability of an artificial pancreas,  told Reuters in a telephone interview.

He said the new draft guidance gives researchers and  medical device makers a clear set of requirements for approving  clinical trials that can show the technology is safe in  real-world settings.

“We’re showing them a path that I think can get them to a  safe and effective product in the U.S.,” he said.

The devices are meant to help the 3 million Americans with  type 1 diabetes, a disease in which the immune system destroys  cells in the pancreas that make insulin.

Patients must monitor their blood sugar and inject  themselves with insulin throughout the day to prevent diabetic  complications such as blindness, and heart and kidney disease.

An artificial pancreas would continuously monitor blood  glucose levels and automatically deliver the right amount of  insulin to the body when it was needed. But the potential for  malfunction of these complex devices to cause serious harm  raises the stakes for proving their safety.

“We understand how this device could change the lives of  millions of Americans with diabetes, and we want our safety and  effectiveness review to give patients the confidence that the  device works,” said Dr. Jeffrey Shuren, director of the FDA’s  Center for Devices and Radiological Health.